Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pharyngitis01:23

Chronic Pharyngitis

12.2K
Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
12.2K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

750
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
750
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

808
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
808
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

376
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
376
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

742
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
742
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic oligonucleotide ASC1R shows excellent tolerability and remarkable efficacy in reducing SARS-CoV-2 mRNA levels in C57BL/6 mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2024
Same author

Advancements in Chronic Myeloid Leukemia detection: Development and evaluation of a novel QCM aptasensor for use in clinical practice.

Biochemistry and biophysics reports·2024
Same author

ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells.

American journal of physiology. Cell physiology·2024
Same author

Long-Term Accumulation, Biological Effects and Toxicity of BSA-Coated Gold Nanoparticles in the Mouse Liver, Spleen, and Kidneys.

International journal of nanomedicine·2024
Same author

Plate reader spectroscopy as an alternative to atomic absorption spectroscopy for the assessment of nanoparticle cellular uptake.

Heliyon·2022
Same author

Surface coating determines the inflammatory potential of magnetite nanoparticles in murine renal podocytes and mesangial cells.

RSC advances·2022

Related Experiment Video

Updated: Feb 9, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.0K

Chronic myelogenous leukemia on target.

Veronika Némethová1, Filip Rázga1

  • 1Department for Biomaterials Research, Polymer Institute of the Slovak Academy of Sciences, Bratislava, Slovakia.

Cancer Medicine
|June 16, 2018
PubMed
Summary

New antisense strategies show promise for treating chronic myelogenous leukemia (CML) by targeting CML stem cells. Advances in mRNA recognition may reduce off-target effects, improving treatment efficacy.

Keywords:
BCR-ABL1antisense therapychronic myelogenous leukemiaselective interactiontarget recognition

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.5K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.2K

Related Experiment Videos

Last Updated: Feb 9, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.0K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.5K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.2K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic myelogenous leukemia (CML) is often treated with tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 oncoprotein.
  • TKIs face challenges including off-target effects, drug resistance, and limited efficacy against CML stem cells (SCs).
  • Eradicating CML SCs is crucial for achieving sustainable treatment outcomes.

Purpose of the Study:

  • To explore alternative treatment strategies for CML, focusing on overcoming TKI limitations.
  • To investigate the potential of antisense strategies for targeting CML stem cells.
  • To address and mitigate off-target effects associated with antisense therapies.

Main Methods:

  • Review of current TKI limitations in CML treatment.
  • Exploration of antisense strategies as an alternative therapeutic approach.
  • Examination of recent advances in antisense drug design, including mRNA recognition concepts.

Main Results:

  • Antisense strategies show potential for targeting primitive CML cell types, including SCs.
  • Current antisense drugs face significant challenges with off-target effects.
  • Novel mRNA recognition concepts offer a potential solution to reduce off-target effects.

Conclusions:

  • Antisense strategies represent a promising avenue for CML treatment, particularly for eradicating CML SCs.
  • Advances in mRNA recognition are critical for developing safer and more effective antisense therapies.
  • The development of targeted antisense drugs could bridge the gap between preclinical research and clinical application in CML therapy.